These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 27483697)
1. NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY. Strat AL; Ghiciuc CM; Lupuşoru CE; Mitu F Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):228-32. PubMed ID: 27483697 [TBL] [Abstract][Full Text] [Related]
2. PCSK9 inhibitors: an overview on a new promising lipid-lowering therapy. Denegri A; Petrova-Slater I; Pasotti E; Rossi MG; Pedrazzini GB; Moccetti T; Moccetti M J Cardiovasc Med (Hagerstown); 2016 Apr; 17(4):237-44. PubMed ID: 26855411 [TBL] [Abstract][Full Text] [Related]
3. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748 [TBL] [Abstract][Full Text] [Related]
4. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]
5. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Fitzgerald K; Frank-Kamenetsky M; Shulga-Morskaya S; Liebow A; Bettencourt BR; Sutherland JE; Hutabarat RM; Clausen VA; Karsten V; Cehelsky J; Nochur SV; Kotelianski V; Horton J; Mant T; Chiesa J; Ritter J; Munisamy M; Vaishnaw AK; Gollob JA; Simon A Lancet; 2014 Jan; 383(9911):60-68. PubMed ID: 24094767 [TBL] [Abstract][Full Text] [Related]
6. [PCSK9 inhibitors and dyslipidemias: an update on clinical evidence]. Norata GD G Ital Cardiol (Rome); 2014 May; 15(5):301-5. PubMed ID: 25002170 [TBL] [Abstract][Full Text] [Related]
7. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
8. Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody. Roth EM; Diller P Future Cardiol; 2014 Mar; 10(2):183-99. PubMed ID: 24762246 [TBL] [Abstract][Full Text] [Related]
9. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement]. Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease. Okere AN; Serra C Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279 [TBL] [Abstract][Full Text] [Related]
13. Update of Clinical Trials of Anti-PCSK9 Antibodies. Wu NQ; Li S; Li JJ Cardiovasc Drugs Ther; 2015 Apr; 29(2):159-69. PubMed ID: 25916406 [TBL] [Abstract][Full Text] [Related]
14. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications. Farnier M Am J Cardiovasc Drugs; 2011 Jun; 11(3):145-52. PubMed ID: 21619378 [TBL] [Abstract][Full Text] [Related]